

Rev. 02 DoC No. DOC-DC-0094238 Reference to. DC-0094238

EU DECLARATION OF CONFORMITY

We, TERUMO CORPORATION

44-1, 2-chome, Hatagaya, Shibuya-ku, Tokyo 151-0072, Japan with Single Registration Number: JP-MF-000017478

being the manufacturer of:

CAPIOX FX

[EXTRACORPOREAL CIRCULATION KITS]

Intended purpose:

CAPIOX FX25

The CAPIOX FX25 is intended to be used during open heart surgical procedures requiring cardiopulmonary bypass for periods up to 6 hours. The CAPIOX FX25 is for use with patients when required blood flow rate will not exceed 7L/min. The CAPIOX FX25 Hardshell Reservoir is also intended for use in vacuum assisted venous drainage procedure, in post-operative chest drainage and autotransfusion procedures to aseptically return the blood to the patient for blood volume replacement. The Integral Arterial Filter is intended to filtrate non-biologic particles and emboli and to facilitate gaseous emboli removal from the blood flowing through a cardiopulmonary bypass circuit. This device shall only be used by properly trained and qualified personnel.

CAPIOX FX15

The CAPIOX FX15 is intended to be used during open heart surgical procedures requiring cardiopulmonary bypass for periods up to 6 hours. The CAPIOX FX15 is for use with patients when required blood flow rate will not exceed 5 L/min (4 L/min if using product codes CX*FX15RW30 or CX*FX15RE30). The CAPIOX FX15 Hardshell Reservoir is also intended for use in vacuum assisted venous drainage procedure, in post-operative chest drainage and autotransfusion procedures to aseptically return the blood to the patient for blood volume replacement. The Integral Arterial Filter is intended to filtrate non-biologic particles and emboli and to facilitate gaseous emboli removal from the blood flowing through a cardiopulmonary bypass circuit. This device shall only be used by properly trained and qualified personnel.

CAPIOX FX05

The CAPIOX FX05 is intended to be used during open heart surgical procedures to transfer oxygen and remove carbon dioxide from blood and to control the blood temperature during cardiopulmonary bypass for periods up to 6 hours. The CAPIOX FX05 is a NEONATE, INFANT oxygenator intended for use in procedures up to maximum flow of 1.5 L/min. The patient weight and BSA should be considered upon use. The FX05 Hardshell Reservoir is also intended for use in vacuum assisted venous drainage procedures. The Integral Arterial Filter is intended to filtrate non-biologic particles and emboli and to facilitate gaseous emboli removal from the blood flowing through a cardiopulmonary bypass circuit. This device shall only be used by properly trained and qualified personnel.



Rev. 02 DoC No. DOC-DC-0094238 Reference to. DC-0094238

Basic UDI-DI: 498735026CXFXP6

Related product codes: See Appendix A (full list of active codes)

declare that the above product of **Class IIa** is in conformity with the applicable requirements of the Regulation (EU) 2017/745 of 5 April 2017 concerning medical devices, and has been subject to the conformity assessment procedure laid down in Article 52.6 of the Regulation, relating to the "Conformity assessment based on a quality management system and on assessment of technical documentation" set out in Annex IX, and by certification of Annex IX Chapter I & III (EU quality management system certificate number HZ 1485480-1), under the supervision of TÜV Rheinland LGA Products GmbH as Notified Body authorized by the GERMAN Competent Authority and carrying the Notified Body No. 0197.

There is no reference to Common Specifications that have been used to within the conformity assessment for Regulation (EU) 2017/745.

Authorised Representative: TERUMO EUROPE N.V. Authorised Address: INTERLEUVENLAAN 40, 3001 LEUVEN, BELGIUM with Single Registration Number: BE-AR-000001433

This EU declaration of conformity is issued under our sole responsibility.

2024-02-29

Tokyo,

(place and date of issue)

- DocuSigned by: Toki hokoshine

Signer Name: Toshio Nakashima Signing Reason: I approve this document Signing Time: 2024-02-29 | 9:53:17 午前 JST — 7CB53CAEA6904D2895AFA45B61783210

Toshio Nakashima General Manager Quality Assurance Department For and on behalf of TERUMO CORPORATION



Rev. 02 DoC No. DOC-DC-0094238 Reference to. DC-0094238

Appendix A – Related product codes

Product code	UDI-DI
CX*FX25E	04987350701060
CX*FX25W	04987350701084
CX*FX25RE	04987350701022
CX*FX25RW	04987350701046
CX*FX15E	04987350701183
CX*FX15W	04987350701206
CX*FX15RE30	04987350701145
CX*FX15RE40	04987350701107
CX*FX15RW30	04987350701169
CX*FX15RW40	04987350701121
CX*FX05E	04987350781710
CX*FX05W	04987350781734
CX*FX05RE	04987350781758
CX*FX05RW	04987350781772

DocuSign

		_ · · · · J.
完了証明書		
エンベロープID: 1317317115274B3A8B282C37003	31A9D0	ステータス: 完了
件名: DocuSignで送信: CAPIOX FX_Rev02		
ソースエンベロープ:		
文書ページ数:3	署名: 1	エンベロープ差出人:
証明書ページ数:5	イニシャル: 0	Saya Shiraishi
自動ナビゲーション: 有効		3-20-2 Nishi-Shinjuku
エンベロープIDスタンプ: 有効		Tokyo Opera City Tower 49F
タイムゾーン: (UTC+09:00)大阪、札幌、東京		Shinjuku-ku, Tokyo 163-1450
		Saya_Shiraishi@terumo.co.jp
		IPアドレス: 60.87.174.213
レコードの追跡		
ステータス: オリジナル	保持者: Saya Shiraishi	場所: DocuSign
2024-02-28 19:33	Saya_Shiraishi@terumo.co.jp	
ステータス: オリジナル	保持者: 品質保証部 文書管理用アカウント	場所: DocuSign
2024-02-29 09:53	ML-TC-QAD_DocuSign@terumo.co.jp	
署名者イベント	署名	タイムスタンプ
Toshio Nakashima		送信: 2024-02-28 19:35
Toshio_Nakashima@terumo.co.jp	Tolio hakesting	表示: 2024-02-29 09:52
セキュリティレベル: メール, アカウント認証(必須)		署名: 2024-02-29 09:53
	署名の選択: 署名画像のアップロード	
	署名ID:	
	7CB53CAE-A690-4D28-95AF-A45B61783210	
	使用IPアドレス: 61.208.155.162	
	DocuSignパスワードによる署名認証	
	署名の理由付き(各タブ上):	
	I approve this document	
電子記録および電子署名の開示条件:		
同意: 2024-02-29 08:51 ID: 85e30b0c-ea22-415d-9572-72db167033e2		
ID. 65630000-6822-4150-9572-720016703362		
同席署名者イベント	署名	タイムスタンプ
編集者配信イベント	ステータス	タイムスタンプ
	~) /~	212722
代理人配信イベント	ステータス	タイムスタンプ
ᆆᄉᆇᇒᇋᆺᄣᆞᆘ	7 -	$a / l = a \cdot d$
仲介者配信イベント	ステータス	タイムスタンプ
証明書付き配信イベント	ステータス	タイムスタンプ
カーボンコピーイベント	ステータス	タイムスタンプ
Saya Shiraishi		
Saya_Shiraishi@terumo.co.jp	コピー済み	送信: 2024-02-29 09:53
TERUMO CORPORATION		表示: 2024-02-29 09:53

署名: 2024-02-29 | 09:53

TERUMO CORPORATION

セキュリティレベル: メール, アカウント認証(必須)

カーボンコピーイベント	ステータス	タイムスタンプ
電子記録および電子署名の開示条件: DocuSignで設定されていません		
馬場 允史	コピー済み	送信: 2024-02-29 09:53
Masafumi_Baba@terumo.co.jp		
セキュリティレベル: メール, アカウント認証(必須)	
電子記録および電子署名の開示条件: DocuSignで設定されていません		
佐藤 圭佑	コピー済み	送信: 2024-02-29 09:53
Keisuke_Sato@terumo.co.jp		
TERUMO CORPORATION		
セキュリティレベル: メール, アカウント認証(必須)	
電子記録および電子署名の開示条件: DocuSignで設定されていません		
立会人イベント	署名	タイムスタンプ
公証人イベント	署名	タイムスタンプ
エンベロープ概要イベント	ステータス	タイムスタンプ
エンベロープの送信	ハッシュ/暗号化済み	2024-02-28 19:35
証明書付き配信	セキュリティ確認済み	2024-02-29 09:52
署名の完了	セキュリティ確認済み	2024-02-29 09:53
完了	セキュリティ確認済み	2024-02-29 09:53
支払いイベント	ステータス	タイムスタンプ
電子記録および電子署名の開示条件		

以下の条件は、米国法人、米国住人または署名する契約書が米国法準拠の場合にのみ 適用されます。日本法人及び日本に住む個人の方(署名する契約書が米国法準拠の場 合を除く。)は、お読みいただく必要ありませんので、そのまま「電子記録および電 子署名の使用に同意します」の横のボックスをチェックし「続行」をクリックくださ い。

The below conditions are applicable only to the legal entities established in US, the residents of US and where the contract to be signed is governed by US laws. Companies established outside of US and residents of countries outside of US (except where the contract to be signed is governed by US laws) may skip reading the below, select the check box next to 'I agree to use electronic records and signatures' and click 'CONTINUE'.

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE (ERSD)

From time to time, Terumo Corporation (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. If you could not access the documents through DocuSign system after such time but you wished for us to send you paper copies of any such documents from our office to you, you may request delivery of such paper copies from us without charge by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Terumo Corporation:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To notify Terumo Corporation of change in your email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at HOUMUSHITSU@terumo.co.jp and in the body of such request you must state: your previous email address, your new email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Terumo Corporation

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to HOUMUSHITSU@terumo.co.jp and in

the body of such request you must state your email address, full name, mailing address, and telephone number.

To withdraw your consent with Terumo Corporation

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to HOUMUSHITSU@terumo.co.jp and in the body of such request you must state your email, full name, mailing address, and telephone number.

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Terumo Corporation as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Terumo Corporation during the course of your relationship with Terumo Corporation.